Phase 1b Open-Label, Dose-Identification Study of XPro1595 in Patients With Mild to Moderate Alzheimer’s Disease With Elevated High Sensitivity C-reactive Protein in Blood. The gene discussed is CRP; the disease is early-onset autosomal dominant Alzheimer disease.